Cargando…

Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity

We previously reported a functional humanized bispecific diabody (bsDb) that targeted EGFR and CD3 (hEx3-Db) and enhancement of its cytotoxicity by rearranging the domain order in the V domain. Here, we further dissected the effect of domain order in bsDbs on their cross-linking ability and binding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asano, Ryutaro, Nagai, Keisuke, Makabe, Koki, Takahashi, Kento, Kumagai, Takashi, Kawaguchi, Hiroko, Ogata, Hiromi, Arai, Kyoko, Umetsu, Mitsuo, Kumagai, Izumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862623/ https://www.ncbi.nlm.nih.gov/pubmed/29568402 http://dx.doi.org/10.18632/oncotarget.24490

Ejemplares similares

Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats
por: Asano, Ryutaro, et al.
Publicado: (2020)

Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation
por: Kuwahara, Atsushi, et al.
Publicado: (2020)

Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics
por: Asano, Ryutaro, et al.
Publicado: (2014)

Anti‐EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half‐life
por: Asano, Ryutaro, et al.
Publicado: (2016)

Construction of IgG–Fab(2) bispecific antibody via intein-mediated protein trans-splicing reaction
por: Yamada, Risa, et al.
Publicado: (2023)

Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method
por: Sanada, Hideaki, et al.
Publicado: (2018)

Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach
por: Ueda, Asami, et al.
Publicado: (2020)

A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity
por: Sugiyama, Aruto, et al.
Publicado: (2017)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Makabe, Koki, et al.
Publicado: (2021)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
por: Yuan, Qingyun, et al.
Publicado: (2021)

Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance
por: Suzuki, Saori, et al.
Publicado: (2018)

Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity
por: Mølgaard, K, et al.
Publicado: (2017)

DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents
por: Chooniedass, Shilpa, et al.
Publicado: (2016)

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
por: Bühler, P., et al.
Publicado: (2007)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
por: Kamakura, Daisuke, et al.
Publicado: (2021)

Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose
por: Bhatnagar, Pravin K., et al.
Publicado: (2008)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Functional integration of protein A binding ability to antibody fragments for convenient and tag-free purification
por: Kuwahara, Atsushi, et al.
Publicado: (2023)

Generation and Characterization of a Diabody Targeting the α(v)β(6) Integrin
por: Kogelberg, Heide, et al.
Publicado: (2013)

Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
por: Mandrup, Ole A., et al.
Publicado: (2021)

Engineering of Bispecific Affinity Proteins with High Affinity for ERBB2 and Adaptable Binding to Albumin
por: Nilvebrant, Johan, et al.
Publicado: (2014)

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
por: Negri, D. R., et al.
Publicado: (1995)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo
por: Xiong, Chenghao, et al.
Publicado: (2018)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation
por: Kamakura, Daisuke, et al.
Publicado: (2020)

Inhibition activity of a disulfide-stabilized diabody against basic fibroblast growth factor in lung cancer
por: Cai, Yaxiong, et al.
Publicado: (2017)

Fermentation, Purification, and Tumor Inhibition of a Disulfide-Stabilized Diabody Against Fibroblast Growth Factor-2
por: Zhang, Simin, et al.
Publicado: (2021)

Orthogonal Protein Purification Facilitated by a Small Bispecific Affinity Tag
por: Nilvebrant, Johan, et al.
Publicado: (2012)

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Publicado: (2021)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
por: Lum, Lawrence G., et al.
Publicado: (2020)

Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
por: Zhang, Caiyun, et al.
Publicado: (2021)

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
por: Adams, G. P., et al.
Publicado: (1998)

Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface
por: Kim, Jin Hong, et al.
Publicado: (2016)

Distinguishing Between Monomeric scFv and Diabody in Solution Using Light and Small Angle X-ray Scattering
por: Lüdel, Frank, et al.
Publicado: (2019)

Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours
por: Huang, Manley T. F., et al.
Publicado: (2022)

Positron emission tomography imaging with (89)Zr-labeled anti-CD8 cys-diabody reveals CD8(+) cell infiltration during oncolytic virus therapy in a glioma murine model
por: Kasten, Benjamin B., et al.
Publicado: (2021)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

Construction of a disulfide‐stabilized diabody against fibroblast growth factor‐2 and the inhibition activity in targeting breast cancer
por: Cai, Yaxiong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5t3hlqp1i568ln9h8jbo8vlhf7